Li Xie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Li Xie has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Jinzhuang Liao
Department of Radiology, The Third Xiangya Hospital of Central South University, Changsha, China
1 shared publication Ruirui Wang
Department of Radiology, The Third Xiangya Hospital, Central South University, Changsha, China
1 shared publicationWei Li
Department of Radiology, The Third Xiangya Hospital, Central South University, Changsha, China
1 shared publicationWenbin Liu
Department of Pathology, Hunan Cancer Hospital, Changsha, China
1 shared publicationXiaoying Li
Department of Radiology, The Third Xiangya Hospital, Central South University, Changsha, China
1 shared publication- Zhongsu Zhou
The Third Hospital of Changsha, Changsha, China
1 shared publication
Latest Publications
- Open Access
- 2 October 2023
- Published by Springer Nature in Cell Death Discovery
- Vol. 9 (1) , 1-13
Gastrodin overcomes chemoresistance via inhibiting Skp2-mediated glycolysis
Aerobic glycolysis, a typical phenotype in human tumors, is associated with tumor progression and chemotherapy resistance. The present study demonstrated that cisplatin-resistant oral squamous cell carcinoma (OSCC) cells exerted a stronger glycolysis ability, which was associated with hexokinase 2 (HK2) overexpression. Additionally, the tumor growth of OSCC cells was delayed in vivo and the glycolysis was notably decreased following HK2 knockdown. The natural compound screening revealed that gastrodin could be an effective candidate for OSCC therapy since it inhibited HK2-mediated glucose metabolism and promoted endogenous OSCC cell apoptosis. Furthermore, gastrodin could bind to protein kinase B (Akt) and suppress its activity, thus downregulating HK2 at the transcriptional level. Additionally, S-phase kinase-associated protein 2 (Skp2) was highly expressed in OSCC cells, while K63-linked ubiquitination of Akt was inhibited in Skp2-depleted cisplatin-resistant OSCC cells. Gastrodin could also inhibit the cisplatin resistance of OSCC cells in vivo, particularly when combined with the Skp2 inhibitor, SZL P1-41. Overall, the aforementioned finding suggested that targeting the Skp2-Akt axis could be a potential therapeutic strategy for treating OSCC and overcoming chemoresistance.
- 2 October 2023
- Published by Springer Nature in Cell Death Discovery
- Vol. 9 (1) , 1-13
Open AccessGastrodin overcomes chemoresistance via inhibiting Skp2-mediated glycolysis
Aerobic glycolysis, a typical phenotype in human tumors, is associated with tumor progression and chemotherapy resistance. The present study demonstrated that cisplatin-resistant oral squamous cell carcinoma (OSCC) cells exerted a stronger glycolysis ability, which was associated with hexokinase 2 (HK2) overexpression. Additionally, the tumor growth of OSCC cells was delayed in vivo and the glycolysis was notably decreased following HK2 knockdown. The natural compound screening revealed that gastrodin could be an effective candidate for OSCC therapy since it inhibited HK2-mediated glucose metabolism and promoted endogenous OSCC cell apoptosis. Furthermore, gastrodin could bind to protein kinase B (Akt) and suppress its activity, thus downregulating HK2 at the transcriptional level. Additionally, S-phase kinase-associated protein 2 (Skp2) was highly expressed in OSCC cells, while K63-linked ubiquitination of Akt was inhibited in Skp2-depleted cisplatin-resistant OSCC cells. Gastrodin could also inhibit the cisplatin resistance of OSCC cells in vivo, particularly when combined with the Skp2 inhibitor, SZL P1-41. Overall, the aforementioned finding suggested that targeting the Skp2-Akt axis could be a potential therapeutic strategy for treating OSCC and overcoming chemoresistance.